Tandem Diabetes Care, Inc.

BOVESPA:T2ND34 Stock Report

Market Cap: R$15.1b

Tandem Diabetes Care Past Earnings Performance

Past criteria checks 0/6

Tandem Diabetes Care's earnings have been declining at an average annual rate of -47.4%, while the Medical Equipment industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 17.8% per year.

Key information

-47.4%

Earnings growth rate

-45.4%

EPS growth rate

Medical Equipment Industry Growth12.3%
Revenue growth rate17.8%
Return on equity-58.4%
Net Margin-17.1%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Tandem Diabetes Care makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BOVESPA:T2ND34 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24796-136361180
31 Mar 24770-141350174
31 Dec 23748-223350170
30 Sep 23771-208364163
30 Jun 23790-224355157
31 Mar 23795-204352148
31 Dec 22801-95336139
30 Sep 22791-68309133
30 Jun 22766-13290120
31 Mar 227386276107
31 Dec 217031626292
30 Sep 216612224580
30 Jun 21605723072
31 Mar 21542-2521467
31 Dec 20499-3420564
30 Sep 20439-4919659
30 Jun 20410-4219055
31 Mar 20394-1718050
31 Dec 19362-2516645
30 Sep 19330-2415241
30 Jun 19282-5513737
31 Mar 19223-11311933
31 Dec 18184-12310529
30 Sep 18148-1389426
30 Jun 18129-1198523
31 Mar 18116-828422
31 Dec 17108-738621
30 Sep 1796-768419
30 Jun 1782-908520
31 Mar 1783-878420
31 Dec 1684-838319
30 Sep 1684-818419
30 Jun 1688-708318
31 Mar 1681-728117
31 Dec 1573-727917
30 Sep 1562-797817
30 Jun 1559-797816
31 Mar 1554-797616
31 Dec 1450-807516
30 Sep 1442-856915
30 Jun 1436-786213
31 Mar 1432-745612
31 Dec 1329-634511

Quality Earnings: T2ND34 is currently unprofitable.

Growing Profit Margin: T2ND34 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: T2ND34 is unprofitable, and losses have increased over the past 5 years at a rate of 47.4% per year.

Accelerating Growth: Unable to compare T2ND34's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: T2ND34 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.9%).


Return on Equity

High ROE: T2ND34 has a negative Return on Equity (-58.36%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies